Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) EBITDA (2016 - 2025)

Historic EBITDA for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$66.6 million.

  • Celldex Therapeutics' EBITDA fell 7252.74% to -$66.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$226.1 million, marking a year-over-year decrease of 4978.07%. This contributed to the annual value of -$157.9 million for FY2024, which is 1325.58% down from last year.
  • Latest data reveals that Celldex Therapeutics reported EBITDA of -$66.6 million as of Q3 2025, which was down 7252.74% from -$56.8 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' EBITDA registered a high of -$13.4 million during Q2 2021, and its lowest value of -$66.6 million during Q3 2025.
  • Its 5-year average for EBITDA is -$34.7 million, with a median of -$33.9 million in 2024.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 17328.7% in 2022, then surged by 1636.88% in 2023.
  • Quarter analysis of 5 years shows Celldex Therapeutics' EBITDA stood at -$20.8 million in 2021, then decreased by 20.73% to -$25.1 million in 2022, then tumbled by 67.76% to -$42.1 million in 2023, then decreased by 16.46% to -$49.1 million in 2024, then plummeted by 35.77% to -$66.6 million in 2025.
  • Its EBITDA stands at -$66.6 million for Q3 2025, versus -$56.8 million for Q2 2025 and -$53.5 million for Q1 2025.